Optimized human cell products for research
and drug discovery

News & Events

DefiniGEN Licenses Cholangiocyte Stem Cell Technology from Cambridge Enterprise

Posted on

Cambridge, UK, 26 April 2017: DefiniGEN, a leading provider of stem cell products and services, today announced that it has strengthened its IP portfolio with a licence for cutting-edge cholangiocyte liver technology from Cambridge Enterprise, the commercialisation arm of the University of Cambridge. The technology will be used by DefiniGEN to develop optimised liver cell […]

DefiniGEN to attend: Advances in Cell-Based Screening for Drug Discovery 2016

Posted on

The Use of Genome Editing and iPS Directed Differentiation Systems to Model Human Liver and Pancreatic Disease in vitro   (by Dr. Marcus Yeo, Chief Executive Officer, DefiniGEN) Dr Marcus Yeo will be overviewing the use of CRISPR gene-editing in combination with induced Pluripotent (iPS) cell differentiation platforms to generate liver and pancreatic disease modelled […]

DefiniGEN to launch iPSC-Derived pancreatic cells, WT hepatocytes and novel metabolic disease models at ISSCR 2016

Posted on

Leading Cambridge human cell product company to present ground-breaking liver hepatocyte and pancreatic beta cell products for disease modelling and drug discovery applications.  Cambridge, UK, 20 June 2016: DefiniGEN, a biotechnology company specializing in the supply of human induced pluripotent stem cell (iPSC)-derived cells has expanded its range of drug discovery and disease modelling tools. […]

DefiniGEN Raises £1.5M ($2.2M USD) in Follow-on Funding Investment

Posted on

Investment will be used to fund commercial launch of new pancreatic and lung stem cell products for drug discovery and regenerative medicine  DefiniGEN, a leading provider of stem cell life science products, has announced that it has raised £1.5m ($2.29m) in follow-on funding. The round was led by Cambridge Enterprise, the commercialization arm of the […]

DefiniGEN and Biospire Japan Ltd have organised a scientific seminar in Kyoto – Japan on 22nd March 2016,

Posted on

Professor Ludovic Vallier Anne McLaren Laboratory for Regenerative Madicine, University of Cambridge Ludovic Vallier is Professor of Regenerative Medicine aliated to the Department of Surgery Cambridge University, Senior Group Leader jointly based at the Cambridge Stem Cell Institute and the Welcome Trust Sanger Institute, and director of the Cambridge Biomedical Research Centre hIPSCs core facility. […]